Articles tagged "Survival"

2021 American Transplant Congress
Adult Combined Liver-Heart Transplantation: The United States Experience
I. A. Ziogas¹, S. P. Alexopoulos¹, W. K. Wu¹, L. K. Matsuoka¹, M. A. Rauf¹, M. Izzy², R. Perri², K. H. Schlendorf³, J. N. Menachem³, A. S. Shah⁴
¹Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN, ³Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN
*Purpose: Combined heart-liver transplantation (CHLT) is now being practiced with increasing regularity and improved outcomes in the United States. We performed the most comprehensive review…
2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
S. Prockop¹, L. Gamelin², R. Dinavahi², Y. Sun², N. Guzman-Becerra², H. Parmar²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Atara Biotherapeutics, South San Francisco, CA
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2021 American Transplant Congress
Kidney Transplantation Outcomes Over Last Six Decades- A Single-center Experience
A. Dinesh¹, S. Jackson², A. Matas¹
¹University of Minnesota Medical School, Minneapolis, MN, ²Analytics Consulting Services, M Health Fairview, Minneapolis, MN
*Purpose: During the last 6 decades, the science around kidney transplantation has evolved tremendously resulting in significant improvements in kidney allograft and patient survival. There…
2021 American Transplant Congress
Textbook Outcome: A Novel Metric in Lung Transplantation Outcomes
A. M. Ganapathi¹, B. A. Whitson¹, N. A. Mokadam¹, B. C. Keller², A. Logan¹, G. Brock¹, K. Washburn¹, A. D. Schenk¹
¹Surgery, Ohio State University Wexner Medical Center, Columbus, OH, ²Medicine, Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Lung transplant programs are typically assessed based on 1-/3-year survival, however other factors such as quality of life, freedom from rejection and oxygen, etc.,…
2021 American Transplant Congress
Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol
B. Natarajan¹, P. Tabrizian², M. Hoteit³, C. Frenette⁴, T. Ghaziani⁵, R. Dhanasekaran⁵, N. Parikh⁶, J. Guy⁷, A. Shui¹, S. Florman², F. Yao¹, N. Mehta¹
¹UCSF, SF, CA, ²Mt Sinai, NY, NY, ³U Penn, Philadelphia, PA, ⁴Scripps, La Jolla, CA, ⁵Stanford, Palo Alto, CA, ⁶U Michigan, Ann Arbor, MI, ⁷CPMC, SF, CA
*Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…
2021 American Transplant Congress
Impact of Lung Allocation Score Cohort Update
M. Skeans¹, A. Wey¹, E. Lease², C. Lehr³, M. Valapour³
¹SRTR, Minneapolis, MN, ²Univ of Washington, Seattle, WA, ³Cleveland Clinic, Cleveland, OH
*Purpose: The lung allocation score (LAS) was last revised in February, 2015, based on waitlist (WL) and posttransplant (PT) survival model cohorts from 2006-2008 and…
2021 American Transplant Congress
Cardiac Outcomes in Isolated Heart and Simultaneous Kidney and Heart Transplants in the US
K. A. Agarwal¹, H. Patel¹, N. Agrawal¹, F. Cardarelli¹, N. Goyal²
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Tufts Medical Center, Boston, MA
*Purpose: Kidney dysfunction is not uncommon in patients with advanced heart failure. Simultaneous kidney and heart transplants (SKHT) have gained acceptance as treatment for patients…
2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
T. Schachtner, J. Fuhrmann, T. Mueller
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
2021 American Transplant Congress
Pre-Procurement Cardiac Arrest in Lung Allograft Donors and Effects on Recipient Outcomes
T. J. Hathaway, E. C. Klipsch, D. Roe, C. Hage, M. Duncan, R. S. Mangus
Indiana University School of Medicine, Indianapolis, IN
*Purpose: This study seeks to help expand the lung transplant donor pool by demonstrating the safe use of lung allografts from donors who underwent pre-procurement…